Spondyloarthritis & psoriatic arthritis
Apical fibrobullous lung disease in spondyloarthritis patients with biologic DMARDs indication
Study context
- Population
- SpA patients registered with HUR-BIO with indication for bDMARDs (under and/or planned to start), 2010–2021, with at least one chest X-ray3,021 records scanned
- Participants
- 2,489 patients
- Exposure
- SpA patients with apical fibrobullous disease (AFLD) vs those without AFLD
- AFLDn = 36
- Outcome
- Incidence of AFLD and associated factors
Methodological detailsregistry-based (HUR-BIO), records scanned 2010–2021
- Registry-based (HUR-BIO)
- Records scanned 2010–2021
Main finding
As reported in the abstract
AFLD by X-ray and/or CT
AFLD
1.4%
36
Observational data: associations, not effects.
Further findings
Male sex, AFLD vs without AFLD
- More likely male with AFLD
- 28 (77.8%) vs 1321 (53.9%), P = 0.004
Age (years), AFLD vs without AFLD
- Older with AFLD
- 56.3 (10.5) years vs 44.8 (11.4) years, P < 0.001
Heavy smokers, AFLD vs without AFLD
- More likely heavy smokers with AFLD
- 27 (79.4%) vs 1468 (60.9%), P = 0.028
Disease duration (years), AFLD vs without AFLD
- Longer disease duration with AFLD
- 17. 7 (9.7) years vs 11.6 (7) years, P = 0.001
QuantiFERON positivity, AFLD vs without AFLD
- Higher in the AFLD group
- 9 (36%) vs 309 (16.1%), P = 0.013
bDMARD choice
- Adalimumab less preferred and etanercept more frequently preferred in those with AFLD
Original publication
Apical fibrobullous lung disease in spondyloarthritis patients with biologic DMARDs indication. Rheumatology (Oxford). Published 27 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →